Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: findings from a multinational cohort between 2010 and 2019
Daniela K van Santen, Rachel Sacks‐Davis, Ashleigh Stewart, et al.
EClinicalMedicine (2022) Vol. 56, pp. 101810-101810
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies
Rachel Sacks‐Davis, Daniela K van Santen, Anders Boyd, et al.
The Lancet HIV (2024) Vol. 11, Iss. 2, pp. e106-e116
Closed Access | Times Cited: 11
Contemporary Insights into Hepatitis C Virus: A Comprehensive Review
Malik Sallam, Roaa Khalil
Microorganisms (2024) Vol. 12, Iss. 6, pp. 1035-1035
Open Access | Times Cited: 7
Integrating hepatitis C testing and treatment into routine HIV care in Cameroon is feasible
Mathurin Kowo, Liza Coyer, Victor Sini, et al.
Journal of the International AIDS Society (2025) Vol. 28, Iss. 2
Open Access
Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis
Christos Thomadakis, Ilias Gountas, Erika Duffell, et al.
The Lancet Regional Health - Europe (2023) Vol. 36, pp. 100792-100792
Open Access | Times Cited: 12
Medicaid Expansion and Restriction Policies for Hepatitis C Treatment
Nathan W. Furukawa, Susan Z. Ingber, Hasan Symum, et al.
JAMA Network Open (2024) Vol. 7, Iss. 7, pp. e2422406-e2422406
Open Access | Times Cited: 3
Is there still hope for the prophylactic hepatitis C vaccine? A review of different approaches
Piotr Rzymski, Aliyu Tijani Jibril, Laila Rahmah, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 9
Closed Access | Times Cited: 3
Viral hepatitis in persons living with HIV in the post-COVID era
Vincent Soriano, Víctor Moreno‐Torres, Carmen de Mendoza, et al.
Aids Reviews (2023) Vol. 25, Iss. 1
Open Access | Times Cited: 8
Hepatitis C virus reinfection incidence among gay and bisexual men with HIV in Australia from 2016 to 2020
Brendan Harney, Rachel Sacks‐Davis, Daniela K van Santen, et al.
Liver International (2024) Vol. 44, Iss. 4, pp. 1024-1031
Open Access | Times Cited: 2
Evolving AIDS- and non-AIDS Mortality and Predictors in the PISCIS Cohort of People Living With HIV in Catalonia and the Balearic Islands (Spain), 1998–2020
Daniel K. Nomah, Suju Jamarkattel, Andreu Bruguera, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 4
Open Access | Times Cited: 2
Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective study
Pablo Ryan, Jorge Valencia, Guillermo Cuevas, et al.
Eurosurveillance (2024) Vol. 29, Iss. 29
Open Access | Times Cited: 2
Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study
Cas J. Isfordink, Anders Boyd, Rachel Sacks‐Davis, et al.
The Lancet Public Health (2023) Vol. 8, Iss. 4, pp. e294-e304
Open Access | Times Cited: 5
Long‐term trends in hepatitis C prevalence, treatment uptake and liver‐related events in the Swiss HIV Cohort Study
Lukas Baumann, Dominique L. Braun, Matthias Cavassini, et al.
Liver International (2023) Vol. 44, Iss. 1, pp. 169-179
Open Access | Times Cited: 5
All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019
Maria-Bernarda Requena, Camélia Protopopescu, Ashleigh C. Stewart, et al.
International Journal of Drug Policy (2024) Vol. 124, pp. 104311-104311
Closed Access | Times Cited: 1
Risk of Primary Incident Hepatitis C Infection Following Bacterial Sexually Transmissible Infections Among Gay and Bisexual Men in Australia From 2016 to 2020
Brendan Harney, Rachel Sacks‐Davis, Paul A. Agius, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 4
Open Access | Times Cited: 1
Annual hepatitis C testing and positive tests among gay and bisexual men in Australia from 2016 to 2022: a serial cross-sectional analysis of sentinel surveillance data
Brendan L Harney, Rachel Sacks‐Davis, Michael W. Traeger, et al.
Sexually Transmitted Infections (2024) Vol. 100, Iss. 5, pp. 295-301
Open Access | Times Cited: 1
An Increase in the Prevalence of Clinically-Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV Sequences
Roaa Khalil, Kholoud Al-Mahzoum, Muna Barakat, et al.
(2024)
Open Access | Times Cited: 1
Cohort Profile: International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC)
Daniela K van Santen, Ashleigh C. Stewart, Joseph Doyle, et al.
International Journal of Epidemiology (2023) Vol. 53, Iss. 1
Open Access | Times Cited: 2
The Application of Australian Rights Protections to the Use of Hepatitis C Notification Data to Engage People ‘Lost to Follow Up’
Freya Saich, Shelley Walker, Margaret Hellard, et al.
Public Health Ethics (2024) Vol. 17, Iss. 1-2, pp. 40-52
Open Access
Incidence and prevalence of hepatitis C and B infections among men who have sex with men and transgender women enrolled in a United States HIV vaccine trial
Matthew Scherer, Vijay Nandi, Magdalena E. Sobieszczyk, et al.
Research Square (Research Square) (2024)
Open Access
Evaluating the effect of direct-acting antiviral agent treatment scale-up on Hepatitis C virus prevalence among people who inject drugs in UK
Pantelis Samartsidis, Ross J. Harris, John Dillon, et al.
International Journal of Drug Policy (2024), pp. 104429-104429
Open Access
An Increase in the Prevalence of Clinically Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV Sequences
Roaa Khalil, Kholoud Al-Mahzoum, Muna Barakat, et al.
Pathogens (2024) Vol. 13, Iss. 8, pp. 674-674
Open Access
The Interplay Between Schistosomiasis and Hepatitis C Virus: Battling on Two Fronts
Nahed A. Makhlouf, Ahmed Abu-Elfatth, Tasneem Khaled, et al.
Infectious Diseases & Immunity (2024)
Open Access
Dual‐acting HIV Inhibitors
María‐José Camarasa, Ana‐Rosa San‐Félix, Sonia de Castro
(2024), pp. 451-462
Closed Access
Commentary on Iversen et al.: Adapting public health surveillance and monitoring to reflect how DAAs are changing the epidemiology of hepatitis C virus infection
Ashly E. Jordan
Addiction (2023) Vol. 118, Iss. 5, pp. 912-913
Open Access | Times Cited: 1
The road to hepatitis C virus elimination
Laurent Cotte, Pierre Pradat
The Lancet Public Health (2023) Vol. 8, Iss. 4, pp. e254-e254
Closed Access
Page 1 - Next Page

Scroll to top